Summit Therapeutics (SMMT) insider buying
7 open-market purchases of SMMT by Summit Therapeutics's executives and directors since September 2025, worth $23M in total, from SEC Form 4 filings.
The most recent: Mahkam Zanganeh bought $499,983 on October 21, 2025.
The biggest buyer over the period is Yu Xia: 1 purchase, $10M.
By year
| Year | Purchases | Value |
|---|---|---|
| 2025 | 7 | $23M |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Yu Xia | 1 | $10M |
| Mahkam Zanganeh | 3 | $6M |
| Robert W Duggan | 3 | $6M |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Oct 21, 2025 | Mahkam Zanganeh |
26,680 | $18.74 | $499,983 | Form 4 |
| Oct 21, 2025 | Robert W Duggan |
26,680 | $18.74 | $499,983 | Form 4 |
| Oct 21, 2025 | Yu Xia |
533,617 | $18.74 | $10M | Form 4 |
| Sep 11, 2025 | Mahkam Zanganeh |
5,000 | $18.07 | $90,350 | Form 4 |
| Sep 11, 2025 | Robert W Duggan |
5,000 | $18.07 | $90,350 | Form 4 |
| Sep 10, 2025 | Mahkam Zanganeh |
333,394 | $17.68 | $6M | Form 4 |
| Sep 10, 2025 | Robert W Duggan |
333,394 | $17.68 | $6M | Form 4 |
Questions
Are Summit Therapeutics insiders buying the stock?
7 open-market purchases of SMMT by Summit Therapeutics's executives and directors since September 2025, worth $23M in total, from SEC Form 4 filings. The most recent: Mahkam Zanganeh bought $499,983 on October 21, 2025.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Summit Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.